Hana Müllerova1, Heather Gelhorn2, Hilary Wilson2, Victoria S Benson1, Niklas Karlsson3, Shailendra Menjoge4, Stephen I Rennard5,6, Maggie Tabberer1, Ruth Tal-Singer7, Debora Merrill8, Paul W Jones1,9. 1. Research and Development, GlaxoSmithKline, Uxbridge, United Kingdom. 2. Evidera, Bethesda, Maryland. 3. Research and Development, AstraZeneca, Gothenburg, Sweden. 4. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut. 5. Division of Pulmonary, Critical Care, Sleep and Allergy, Nebraska Medical Center, Omaha. 6. AstraZeneca, Cambridge, United Kingdom. 7. Respiratory Therapy Area Unit, Research and Development, GlaxoSmithKline, King of Prussia, Pennsylvania. 8. COPD Foundation, Washington, D.C. 9. Institute of Infection and Immunity, St George's University of London, United Kingdom.
Abstract
Background: We aimed to estimate the usefulness of a disease specific health status measure, the St George's Respiratory Questionnaire (SGRQ), to predict outcomes in patients with chronic obstructive pulmonary disease (COPD). Methods: Individual patient-data of 12043 patients from long-term randomized clinical trials (2-4 years' duration) in the COPD Biomarkers Qualification Consortium database were analyzed. The adverse COPD outcomes were: exacerbations of COPD, hospital admissions due to exacerbation and all-cause mortality. Cox proportional hazards regression was used to calculate adjusted hazard ratios (HR) and 95% confidence intervals (CIs) for quartiles of SGRQ scores at baseline and time to first event, and time from first to second event, where appropriate. Results: The risk of adverse COPD outcomes increased with each increasing quartile of SGRQ score for all time to first event analyses. When comparing the lowest versus the highest quartile, the event risk (HRs [95% CIs]) increased by 40% for exacerbations (1.40 [1.29, 1.51]); 2-fold for hospital admissions (2.01 [1.78, 2.28]) and more than 2-fold for all-cause mortality (2.30 [1.91, 2.78]). For second event analyses in a subset of eligible patients, these trends persisted albeit with reduced risk estimates for exacerbations. Conclusions: Among patients with COPD, health status measured by a SGRQ score predicted exacerbations of COPD, hospital admissions due to exacerbations and their recurrence and death after adjustment. These data support the rationale for a health status measure use as a drug development tool and suggest that a health status measure may also have a role in risk assessment for COPD patients in routine medical care.
Background: We aimed to estimate the usefulness of a disease specific health status measure, the St George's Respiratory Questionnaire (SGRQ), to predict outcomes in patients with chronic obstructive pulmonary disease (COPD). Methods: Individual patient-data of 12043 patients from long-term randomized clinical trials (2-4 years' duration) in the COPD Biomarkers Qualification Consortium database were analyzed. The adverse COPD outcomes were: exacerbations of COPD, hospital admissions due to exacerbation and all-cause mortality. Cox proportional hazards regression was used to calculate adjusted hazard ratios (HR) and 95% confidence intervals (CIs) for quartiles of SGRQ scores at baseline and time to first event, and time from first to second event, where appropriate. Results: The risk of adverse COPD outcomes increased with each increasing quartile of SGRQ score for all time to first event analyses. When comparing the lowest versus the highest quartile, the event risk (HRs [95% CIs]) increased by 40% for exacerbations (1.40 [1.29, 1.51]); 2-fold for hospital admissions (2.01 [1.78, 2.28]) and more than 2-fold for all-cause mortality (2.30 [1.91, 2.78]). For second event analyses in a subset of eligible patients, these trends persisted albeit with reduced risk estimates for exacerbations. Conclusions: Among patients with COPD, health status measured by a SGRQ score predicted exacerbations of COPD, hospital admissions due to exacerbations and their recurrence and death after adjustment. These data support the rationale for a health status measure use as a drug development tool and suggest that a health status measure may also have a role in risk assessment for COPDpatients in routine medical care.
Authors: Volkert Siersma; Hanne Thorsen; Per E Holstein; Marleen Kars; Jan Apelqvist; Edward B Jude; Alberto Piaggesi; Karel Bakker; Michael Edmonds; Alexandra Jirkovská; Didac Mauricio; Gunnel Ragnarson Tennvall; Heinrich Reike; Maximilian Spraul; Luigi Uccioli; Vilma Urbancic; Kristien van Acker; Jeff van Baal; Nicolaas C Schaper Journal: Diabetes Care Date: 2013-10-29 Impact factor: 19.112
Authors: Paul A Heidenreich; John A Spertus; Philip G Jones; William S Weintraub; John S Rumsfeld; Saif S Rathore; Eric D Peterson; Frederick A Masoudi; Harlan M Krumholz; Edward P Havranek; Mark W Conard; Randall E Williams Journal: J Am Coll Cardiol Date: 2006-01-26 Impact factor: 24.094
Authors: Bartolome R Celli; Nicholas Locantore; Julie Yates; Ruth Tal-Singer; Bruce E Miller; Per Bakke; Peter Calverley; Harvey Coxson; Courtney Crim; Lisa D Edwards; David A Lomas; Annelyse Duvoix; William MacNee; Stephen Rennard; Edwin Silverman; Jørgen Vestbo; Emiel Wouters; Alvar Agustí Journal: Am J Respir Crit Care Med Date: 2012-03-15 Impact factor: 21.405
Authors: Hana Müllerova; Diego J Maselli; Nicholas Locantore; Jørgen Vestbo; John R Hurst; Jadwiga A Wedzicha; Per Bakke; Alvar Agusti; Antonio Anzueto Journal: Chest Date: 2015-04 Impact factor: 9.410
Authors: Jamuna K Krishnan; Kayley M Ancy; Clara Oromendia; Katherine L Hoffman; Imaani Easthausen; Nancy K Leidy; MeiLan K Han; Russell P Bowler; Stephanie A Christenson; David J Couper; Gerard J Criner; Jeffrey L Curtis; Mark T Dransfield; Nadia N Hansel; Anand S Iyer; Robert Paine Iii; Stephen P Peters; Jadwiga A Wedzicha; Prescott G Woodruff; Karla V Ballman; Fernando J Martinez Journal: Chronic Obstr Pulm Dis Date: 2022-04-29
Authors: Robert M Burkes; David J Couper; Igor Z Barjaktarevic; Christopher B Cooper; Wassim W Labaki; Meilan K Han; Prescott G Woodruff; Stephen C Lazarus; Trisha M Parekh; Robert Paine; Alejandro P Comellas; Russell P Bowler; Laura R Loehr; Nirupama Putcha; Robert A Wise; Todd T Brown; M Bradley Drummond Journal: Chronic Obstr Pulm Dis Date: 2021-04-27
Authors: Alexander J Mackay; Konstantinos Kostikas; Nicolas Roche; Stefan-Marian Frent; Petter Olsson; Pascal Pfister; Pritam Gupta; Francesco Patalano; Donald Banerji; Jadwiga A Wedzicha Journal: Respir Res Date: 2020-04-22
Authors: Sabine C Zimmermann; Cindy Thamrin; Andrew Sl Chan; Amy Bertolin; David G Chapman; Gregory G King Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-01-21
Authors: Justin L Garner; Tawimas Shaipanich; Jorine E Hartman; Christopher M Orton; Cielito Caneja; Karin Klooster; John Thornton; Don D Sin; Dirk-Jan Slebos; Pallav L Shah Journal: Eur Respir J Date: 2020-12-17 Impact factor: 16.671